ATS View
한국어

Stcube KRX:052020KOSDAQ

에스티큐브 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h0
Articles, 7 days5
DART filings, 7 days0
Articles tracked22since Sep 11

In Q2 2026, Stcube reported revenue of ₩1.5bn, up 60.7% year on year, and an operating loss of ₩6.1bn. Stcube (에스티큐브) appeared in 5 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 27 with 5 articles. The most common catalyst was clinical & approvals (4).

Filing signals 4 quarters of losses Screener

Stcube quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩1.5bn+60.7%−₩6.1bn−₩5.5bn
Q1 2026₩1.4bn-24.6%−₩7.3bn−₩6.7bn
Q4 2025 derived₩2.7bn+6.9%−₩7.0bn
margin −254.9%		−₩6.6bn
Q3 2025₩1.5bn-53.1%−₩5.8bn−₩5.2bn
Q2 2025₩935m-68.0%−₩5.5bn−₩5.4bn
Q1 2025₩1.8bn-30.6%−₩5.2bn
margin −285.7%		−₩4.6bn
Q4 2024 derived₩2.6bn+112.8%−₩5.6bn
margin −216.7%		−₩4.9bn
Q3 2024₩3.2bn+245.4%−₩6.3bn
margin −197.8%		−₩6.3bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Stcube top stories 2 weeks, by number of outlets

  1. 1
    에스티큐브, 비소세포폐암 임상 2상 중간결과 발표
    2 outlets · 2 articlesFirst report Oct 27 14:27 뉴스핌Clinical trial
  2. 2
    에스티큐브, ‘넬마스토바트’ 폐암 데이터 공개…기술이전 논의 속도
    1 outlets · 1 articlesFirst report Oct 27 15:23 한스경제Licensing deal
  3. 3
    [ESMO] 에스티큐브, 비소세포폐암 2상 중간 결과 발표…환자 등록 73% 달성
    1 outlets · 1 articlesFirst report Oct 27 15:52 더바이오Clinical trial
  4. 4
    에스티큐브 넬마스토바트, 폐암 2상서 반응률 25.7%
    1 outlets · 1 articlesFirst report Oct 27 15:08 메디파나뉴스Clinical trial

Latest Stcube news Korean headlines